Skip to main content
Fig. 1 | Radiation Oncology

Fig. 1

From: Radiosensitization of orthotopic GIC-driven glioblastoma by doxycycline causes skin damage

Fig. 1

Skin damage to NOD-SCID mice bearing orthotopic glioblastoma radiosensitized by chronic DXC administration. a-c H/E staining of brain sections taken at d56, d127 and d137 of tumor development showing progression of orthotopic COMI glioblastoma induced to NOD SCID mice. Immunostaining at d56 (Fig. a-inset) reveals that most of the orthotopic tumor expresses the stem cell marker nestin, indicating its stem cell-driven character. Mouse ID numbers 33.7, 36.6 and 36.10 are indicated for the sake of reference. d, e Skin damage to the shoulders region of DXC-treated mice at d43 of tumor development. DXC was subcutaneously administered daily at 10 mg/kg on weekdays starting d21 of tumor development (d). Control mice were administered with vehicle only (0.9% NaCl) (e). 0.25 Gy of ionizing radiation were delivered to the head of all mice twice a week (Tuesday and Friday) starting at d22 and ending at d130 of tumor development. DXC administration was discontinued at d49 of tumor development due to the deep skin ulcers appearing in DXC-treated mice. f Skin damage to the shoulders region of mice treated with a pure formulation of DXC. 60 mg/kg DXC was subcutaneously administered once on the first day of treatment followed by 10 mg/kg DXC twice daily for a total of 7 days. g Kaplan-Meier survival curves of irradiated animals. Median survival of DXC-treated animals (magenta) was not significantly different from that of vehicle-treated controls (blue) (119 vs. 113 days; ratio: 0.949; P: 0.445). The latter survived significantly longer in comparison to mice treated with standard 3 × 2.5 Gy fractions (black) (113 vs. 93 days; ratio: 1.215; P: 0.0009)

Back to article page